Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Open Access
- 11 March 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6), 1907
- https://doi.org/10.3390/ijms21061907
Abstract
Liver-related diseases are the third-leading causes (9.3%) of mortality in type 2 diabetes (T2D) in Japan. T2D is closely associated with nonalcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma (HCC) and hepatic failure. No pharmacotherapies are established for NASH patients with T2D. Though vitamin E is established as a first-line agent for NASH without T2D, its efficacy for NASH with T2D recently failed to be proven. The effects of pioglitazone on NASH histology with T2D have extensively been established, but several concerns exist, such as body weight gain, fluid retention, cancer incidence, and bone fracture. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and NAFLD (LEAN study, LEAD trial, and E-LIFT study). Among a variety of SGLT2 inhibitors, dapagliflozin has already entered the phase 3 trial (DEAN study). A key clinical need is to determine the kinds of antidiabetic drugs that are the most appropriate for the treatment of NASH to prevent the progression of hepatic fibrosis, resulting in HCC or liver-related mortality without increasing the risk of cardiovascular or renal events. Combination therapies, such as glucagon receptor agonist/GLP-1 or gastrointestinal peptide/GLP-1, are under development. This review focused on antidiabetic agents and future perspectives on the view of the treatment of NAFLD with T2D.This publication has 115 references indexed in Scilit:
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 DiabetesCell Metabolism, 2013
- Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysisBiomedical Reports, 2012
- Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective studyThe Esophagus, 2012
- Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 DiabetesJournal of Diabetes & Metabolism, 2011
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology, 2010
- Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASHThe Esophagus, 2010
- Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver diseaseHepatology, 2010
- Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With DiabetesGastroenterology, 2009
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisHepatology, 1999